Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
about
The Role of PARP Inhibitors in the Treatment of Gynecologic MalignanciesEpidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analysesEpidemiology and natural history of human papillomavirus infections in the female genital tractPapillomavirus genome structure, expression, and post-transcriptional regulationProphylactic human papillomavirus vaccinesIdentification of human papillomavirus type 16 L1 surface loops required for neutralization by human seraRandomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future.Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in malesVirus-like particles production in green plantsHuman papillomavirus and HPV vaccines: a reviewThe viral etiology of AIDS-associated malignanciesKinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvantHow do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked?Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineThe clinical development process for a novel preventive vaccine: An overviewImmunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel diseaseAre the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPVSafety and Efficacy Data on Vaccines and Immunization to Human PapillomavirusCervical cancer control for Hispanic women in Texas: strategies from research and practiceHuman papillomavirus vaccination: a case study in translational scienceCurrent status of human papillomavirus vaccinesLessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsAre the currently existing anti-human papillomavirus vaccines appropriate for the developing world?VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirusEnhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE)Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin-12 DNA induces E7-specific antitumor effects in C57BL/6 miceCapsomer vaccines protect mice from vaginal challenge with human papillomavirusElicitation of protective immune responses using a bivalent H5N1 VLP vaccine.Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer.Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong KongNew quadrivalent HPV vaccine developments.Safety of human papillomavirus vaccines: a review.Alternative technologies in cervical cancer screening: a randomised evaluation trial.A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consentEnrolling adolescents in HIV vaccine trials: reflections on legal complexities from South Africa.Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.Warts (genital)Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission modelA cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.
P2860
Q21129302-08A6F47F-62D2-467B-AD2E-89D6E56B152FQ21144710-08734E91-C2A8-45A2-B0CE-EDDA269F5AA1Q21284469-018E50EA-8DA9-4974-A99A-2F81CDF3C1D4Q22255483-3579B220-BF4A-46E0-88F2-00FB56BB44D5Q24545449-989FAC6D-071E-4782-BE52-48DDD8EC55DBQ24545868-17D807A4-5881-4010-B0DA-A6316FD70570Q24600011-4DDE6781-87C2-428D-BFCC-7AA12E53A968Q24614644-861CEC13-EC2A-498C-B02B-45E21A57BC93Q24650772-FA50F389-77A3-4E4E-B747-A7A9B5D0CA96Q24657891-B49DFA62-9F70-4D9B-8F49-B0A60E1293AAQ24685892-09FC14B7-7E01-4E75-90CB-E33F08D02186Q24802323-BF3FACB1-AEA0-4A1E-9829-8614B2A8D17EQ25257230-FF5FA6A6-8ECD-4D67-9834-DF014EAD92CAQ26749285-43B663CC-970B-4A12-BC7D-A4ECBEA011DDQ26770871-A91BAB59-E06C-4BAA-B280-47B1FDA87820Q26777330-9B3BC578-24AA-42F5-BAF4-92A403BEFE9AQ26783973-3CD2D0C7-E23A-40DE-896E-0E345F0E4E28Q26799574-A4827F1A-94F9-4DE5-B36A-446AFB06E2DFQ26851681-124A02DC-4609-4832-BD88-DC8B61282AC7Q26853556-7D93D2A3-D89A-43F1-A530-37B5AC152597Q26991640-C9E357F2-39F2-40DD-AE02-DBED56F1E7BBQ27013018-2F98D488-C12C-4C00-BD08-0F53F5652EF7Q27692056-91E77948-206B-4E39-8B94-A1FBD0695BB1Q28280059-B0CE4E8E-F59A-43AD-B1AC-D58A326C0978Q28476101-3C080791-F5DD-429B-9A80-E7BDF3F023E7Q28660843-E42E1645-6ECE-46D3-8535-82753FA2DB9AQ28743261-1D7D750E-8804-4033-B2C6-B9415C824351Q30372990-894153B5-FFF3-435E-A898-DDCF1075F628Q30409053-4B346939-FDE7-482F-B485-A6C2746356BFQ31131825-1821B3FE-A6AE-4248-8682-249829C82F81Q33156844-2B09232F-2401-4EFE-97CB-252116D24447Q33162724-AF9ECC10-1C37-4D88-849A-0E036077C7FCQ33260497-CA950116-7B50-493F-AD5C-F16663083FF2Q33273063-5A77ED66-9DC8-4FA5-9E34-AB9D4CC25726Q33284467-55A5BCD8-EBD0-4090-B3FB-3BE126B73D0EQ33292779-7E52623B-6192-4A31-8FED-7B9E5A2DF438Q33448263-A17F3BF7-9C43-4B4B-AB5E-90A8654ACC3EQ33488325-ED7F4A1C-085D-4F69-A897-8650F82406B7Q33514126-94FE1A75-A58F-45AD-9D02-F6CE544D931CQ33523171-A9AFEEF8-F2F7-46A2-8687-034F803BEDAD
P2860
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Prophylactic quadrivalent huma ...... entre phase II efficacy trial.
@ast
Prophylactic quadrivalent huma ...... entre phase II efficacy trial.
@en
Prophylactic quadrivalent huma ...... entre phase II efficacy trial.
@nl
type
label
Prophylactic quadrivalent huma ...... entre phase II efficacy trial.
@ast
Prophylactic quadrivalent huma ...... entre phase II efficacy trial.
@en
Prophylactic quadrivalent huma ...... entre phase II efficacy trial.
@nl
prefLabel
Prophylactic quadrivalent huma ...... entre phase II efficacy trial.
@ast
Prophylactic quadrivalent huma ...... entre phase II efficacy trial.
@en
Prophylactic quadrivalent huma ...... entre phase II efficacy trial.
@nl
P2093
P921
P1433
P1476
Prophylactic quadrivalent huma ...... entre phase II efficacy trial.
@en
P2093
Alex Ferenczy
Alfred J Saah
Anna R Giuliano
Brigitte M Ronnett
Carlos A Petta
Christian Malm
Darron R Brown
Diane M Harper
Eliav Barr
Frank J Taddeo
P304
P356
10.1016/S1470-2045(05)70101-7
P577
2005-05-01T00:00:00Z